TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
Antineoplastic Agents
/ pharmacology
DNA Mutational Analysis
Drug Resistance, Neoplasm
/ genetics
Female
GTP Phosphohydrolases
/ genetics
Genetic Heterogeneity
Humans
Longitudinal Studies
Male
Melanoma
/ genetics
Membrane Proteins
/ genetics
Middle Aged
Mutation
Neoplasms, Second Primary
/ drug therapy
Prospective Studies
Proto-Oncogene Proteins B-raf
/ genetics
Skin
/ pathology
Skin Neoplasms
/ drug therapy
Telomerase
/ genetics
Journal
The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
04
10
2019
revised:
06
12
2019
accepted:
06
01
2020
pubmed:
23
2
2020
medline:
9
3
2021
entrez:
23
2
2020
Statut:
ppublish
Résumé
Mutational heterogeneity can contribute to therapeutic resistance in solid cancers. In melanoma, the frequencies of intertumoral and intratumoral heterogeneity are controversial. We examined mutational heterogeneity within individual patients with melanoma using multiplatform analysis of commonly mutated driver and nonpassenger genes. We analyzed paired primary and metastatic tumors from 60 patients and multiple metastatic tumors from 39 patients whose primary tumors were unavailable (n = 271 tumors). We used a combination of multiplex SNaPshot assays, Sanger sequencing, mutation-specific PCR, or droplet digital PCR to determine the presence of BRAF
Identifiants
pubmed: 32087194
pii: S0022-202X(20)30159-7
doi: 10.1016/j.jid.2020.01.027
pmc: PMC7387168
mid: NIHMS1568745
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Membrane Proteins
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
TERT protein, human
EC 2.7.7.49
Telomerase
EC 2.7.7.49
GTP Phosphohydrolases
EC 3.6.1.-
NRAS protein, human
EC 3.6.1.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1609-1618.e7Subventions
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA225450
Pays : United States
Organisme : FDA HHS
ID : U01 FD004203
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR064184
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA198495
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA154786
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Clin Chem. 2015 Jan;61(1):64-71
pubmed: 25421801
BMC Med. 2017 Jul 18;15(1):133
pubmed: 28716075
J Invest Dermatol. 2016 Jan;136(1):337-8
pubmed: 26763460
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000
pubmed: 26286987
Eur J Cancer. 2017 Aug;81:106-115
pubmed: 28623774
Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):151-161
pubmed: 28110020
Cancer Res. 2016 Aug 15;76(16):4765-74
pubmed: 27216186
Am J Dermatopathol. 2017 Apr;39(4):291-295
pubmed: 28323782
Cancer Cell. 2015 Jan 12;27(1):15-26
pubmed: 25584892
Methods Mol Biol. 2020;2055:155-180
pubmed: 31502151
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Nat Rev Cancer. 2017 Oct;17(10):605-619
pubmed: 28912577
J Clin Oncol. 2012 Jul 10;30(20):2522-9
pubmed: 22614978
Oncotarget. 2016 Nov 22;7(47):77163-77174
pubmed: 27791198
Cold Spring Harb Perspect Med. 2017 Aug 1;7(8):
pubmed: 28289245
Eur J Cancer. 2013 Jan;49(2):395-402
pubmed: 22981500
EMBO Mol Med. 2015 Jun 23;7(9):1104-18
pubmed: 26105199
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
N Engl J Med. 2015 Nov 12;373(20):1926-36
pubmed: 26559571
Mol Cancer Ther. 2012 Dec;11(12):2704-8
pubmed: 22962325
PLoS One. 2014 Jan 06;9(1):e85004
pubmed: 24400126
Cancer Discov. 2014 Jan;4(1):80-93
pubmed: 24265155
PLoS One. 2012;7(1):e29336
pubmed: 22235286
Br J Cancer. 2014 Oct 14;111(8):1678-9
pubmed: 24366302
J Am Acad Dermatol. 2019 Mar;80(3):685-693
pubmed: 30287318
Am J Transl Res. 2009;1(1):35-43
pubmed: 19966936
Br J Cancer. 2011 Feb 1;104(3):464-8
pubmed: 21224857
Oncogene. 2006 Jun 8;25(24):3357-64
pubmed: 16462768
J Mol Diagn. 2019 Mar;21(2):274-285
pubmed: 30827467